Pasithea Therapeutics to present cancer study data showing PAS-004 efficacy

Pasithea Therapeutics announced the publication of data showing that PAS-004, a next-generation macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 and other cancer indications, strongly inhibited NRAS mutant cancer cell lines. Maximal growth inhibition of greater than50% was achieved by PAS-004 in more cell lines than binimetinib and selumetinib. In addition, PAS-004’s cell line inhibition was comparable to trametinib in 5 cell lines tested but, in contrast to trametinib, PAS-004 did not reach a plateau. The results will be presented at the upcoming ASCO Annual Meeting on June 1. PAS-004 is the first macrocyclic MEK inhibitor to enter human clinical trials, with an expected extended half-life which may provide better compliance rates, as well as improved efficacy in NF1.